Long-term follow-up data from 126 patients with recurrent high grade glioma from three phase 1 trials of toca 511 and toca fc: Update and justification for a phase 2/3 trial

Authors

D Jolly
Manish K. Aghi
Michael A. Vogelbaum
Steven N. Kalkanis, Henry Ford HealthFollow
Daniela A. Bota
C C. Chen
B Carter
B Elder
J Engh
S A. Goldlust
G J. Kaptain
S Kesari
J Landolfi
L M. Liau
Tom Mikkelsen, Henry Ford HealthFollow
David Piccioni
Jana Portnow
S Singer
Tobias Walbert, Henry Ford HealthFollow
H Gruber
C Ibanez
L Mitchell
Derek Ostertag
J S. Shorr
L Q. Yang
A Das
Timothy Cloughesy

Recommended Citation

Jolly DJ, Aghi M, Vogelbaum MA, Kalkanis SN, Bota D, Chen CC, Carter B, Elder B, Engh J, Goldlust SA, Kaptain GJ, Kesari S, Landolfi J, Liau LM, Mikkelsen T, Piccioni D, Portnow J, Singer S, Walbert T, Gruber H, Ibanez C, Mitchell L, Ostertag D, Shorr JS, Yang LQ, Das A, and Cloughesy TF. Long-term follow-up data from 126 patients with recurrent high grade glioma from three phase 1 trials of toca 511 and toca fc: Update and justification for a phase 2/3 trial. Mol Ther 2017; 25(5):24-25.

Document Type

Conference Proceeding

Publication Date

2017

Publication Title

Mol Ther

Volume

25

Issue

5

First Page

24

Last Page

25